AR004668A1 - A PURIFIED ISOLATED NUCLEIC ACID, A RECOMBINING VECTOR OF EXPRESSION THAT UNDERSTANDS IT, A CELL THAT INCLUDES SUCH A VECTOR, A METHOD FOR THE PRODUCTION OF A H.PYLORI POLYPEPTIDE, A COMPOSITION OF A VACCINE, A PREPARED COMPOSITION PURIFIED BY H. - Google Patents

A PURIFIED ISOLATED NUCLEIC ACID, A RECOMBINING VECTOR OF EXPRESSION THAT UNDERSTANDS IT, A CELL THAT INCLUDES SUCH A VECTOR, A METHOD FOR THE PRODUCTION OF A H.PYLORI POLYPEPTIDE, A COMPOSITION OF A VACCINE, A PREPARED COMPOSITION PURIFIED BY H.

Info

Publication number
AR004668A1
AR004668A1 ARP960103094A AR10309496A AR004668A1 AR 004668 A1 AR004668 A1 AR 004668A1 AR P960103094 A ARP960103094 A AR P960103094A AR 10309496 A AR10309496 A AR 10309496A AR 004668 A1 AR004668 A1 AR 004668A1
Authority
AR
Argentina
Prior art keywords
vector
purified
composition
nucleic acid
cell
Prior art date
Application number
ARP960103094A
Other languages
Spanish (es)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR004668A1 publication Critical patent/AR004668A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Se describe un ácido nucleico aislado purificado, un vector de expresión recombinante que lo comprende, una célula que comprende dicho vector, un métodopara la producción de un polipéptido de H.pylori, una composición de vacuna, el uso de dicha composición para preparar medicamentos, un polipéptido purificadode H.pylori y un método para la detección de la presencia de un ácido nucleico de H.pylori.A purified isolated nucleic acid, a recombinant expression vector comprising it, a cell comprising said vector, a method for the production of an H.pylori polypeptide, a vaccine composition, the use of said composition to prepare medicaments, is described. a purified H.pylori polypeptide and a method for detecting the presence of a H.pylori nucleic acid.

ARP960103094A 1995-06-07 1996-07-06 A PURIFIED ISOLATED NUCLEIC ACID, A RECOMBINING VECTOR OF EXPRESSION THAT UNDERSTANDS IT, A CELL THAT INCLUDES SUCH A VECTOR, A METHOD FOR THE PRODUCTION OF A H.PYLORI POLYPEPTIDE, A COMPOSITION OF A VACCINE, A PREPARED COMPOSITION PURIFIED BY H. AR004668A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48703295A 1995-06-07 1995-06-07
US56146995A 1995-11-17 1995-11-17
US63040596A 1996-04-01 1996-04-01

Publications (1)

Publication Number Publication Date
AR004668A1 true AR004668A1 (en) 1999-03-10

Family

ID=27413750

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103094A AR004668A1 (en) 1995-06-07 1996-07-06 A PURIFIED ISOLATED NUCLEIC ACID, A RECOMBINING VECTOR OF EXPRESSION THAT UNDERSTANDS IT, A CELL THAT INCLUDES SUCH A VECTOR, A METHOD FOR THE PRODUCTION OF A H.PYLORI POLYPEPTIDE, A COMPOSITION OF A VACCINE, A PREPARED COMPOSITION PURIFIED BY H.

Country Status (4)

Country Link
AR (1) AR004668A1 (en)
NO (1) NO975745L (en)
SK (1) SK165197A3 (en)
WO (1) WO1996040893A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (en) * 1991-10-03 1995-06-09 Pasteur Institut NEW GENES OF HELICOBACTER PYLORI. THEIR USE FOR THE PREPARATION OF RECOMBINANT STRAINS OF H. PYLORI.
US6258359B1 (en) 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
WO1995014093A1 (en) 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
JP4368944B2 (en) * 1995-04-21 2009-11-18 シーエスエル、リミテッド Helicobacter antigen for defense
ES2283012T3 (en) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. HELICOBACTER PYLORI BACTERIOFERRITINE.
US5780278A (en) * 1996-05-20 1998-07-14 Vanderbilt University IceA gene and related methods
EP1021458A4 (en) * 1996-11-14 2001-12-12 Merieux Oravax Helicobacter polypeptides and corresponding polynucleotide molecules
WO1998027819A1 (en) * 1996-12-23 1998-07-02 Vanderbilt University dapE GENE OF HELICOBACTER PYLORI AND dapE- MUTANT STRAINS OF $i(HELICOBACTER PYLORI)
AU6583398A (en) * 1997-03-26 1998-10-20 Avant Immunotherapeutics, Inc. Polypeptides which immunoreact with polyclonal antisera against (h. pylori)
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
AU750792B2 (en) * 1997-04-01 2002-07-25 Human Genome Sciences, Inc. 76 kDa, 32 kDa, and 50 kDa helicobacter polypeptides and corresponding polynucleotide molecules
EP0977864A2 (en) * 1997-04-25 2000-02-09 Genelabs Technologies, Inc. Antigenic composition and method of detection for helicobacter pylori
HUP0003388A3 (en) * 1997-04-30 2001-06-28 Merieux Oravax Anti-helicobacter vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method
US6599509B2 (en) * 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
PT1042001E (en) * 1997-12-16 2002-09-30 Chiron Corp USE OF MICROPARTICLES COMBINED WITH SUBMICronic EMULSES OIL-IN-WATER
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
JPH11221079A (en) * 1998-02-04 1999-08-17 Kyowa Hakko Kogyo Co Ltd Transglycosidase and dna encoding the same enzyme
GB9808423D0 (en) * 1998-04-22 1998-06-17 Glaxo Group Ltd Bacterial polypeptide family
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
NZ508366A (en) * 1998-05-01 2004-03-26 Chiron Corp Neisseria meningitidis antigens and compositions
US6190667B1 (en) 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
US6222026B1 (en) 1998-09-08 2001-04-24 Smithkline Beecham Corporation Gcp
SE9901548D0 (en) * 1999-04-29 1999-04-29 Astra Ab Helicobacter pylori antigens
AU5668400A (en) * 1999-06-28 2001-01-31 National Research Council Of Canada Glycosyltransferases of helicobacter pylori as a new target in prevention and treatment of h. pylori infections
EP1222197A4 (en) * 1999-10-04 2004-07-21 Merck & Co Inc Mray gene and enzyme of pseudomonas aeruginosa
US6861516B1 (en) 1999-10-04 2005-03-01 Merck & Co., Inc. MraY gene and enzyme of pseudomonas aeruginosa
GB0010370D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
GB0010371D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
WO2002000851A2 (en) * 2000-06-28 2002-01-03 National Research Council Of Canada Helicobacter dd-heptosyltransferase
US7537772B1 (en) 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
US7731980B2 (en) 2000-10-02 2010-06-08 Emergent Product Development Gaithersburg Inc. Chlamydia PMP proteins, gene sequences and uses thereof
EP1385861A2 (en) * 2000-10-25 2004-02-04 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
WO2006056487A2 (en) 2004-11-24 2006-06-01 Theraptosis S.A. Peptides useful as dual caspase-2/-6 inhibitors and their biological applications
EP2837939A1 (en) * 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection

Also Published As

Publication number Publication date
WO1996040893A1 (en) 1996-12-19
NO975745L (en) 1998-02-09
NO975745D0 (en) 1997-12-05
SK165197A3 (en) 1999-01-11

Similar Documents

Publication Publication Date Title
AR004668A1 (en) A PURIFIED ISOLATED NUCLEIC ACID, A RECOMBINING VECTOR OF EXPRESSION THAT UNDERSTANDS IT, A CELL THAT INCLUDES SUCH A VECTOR, A METHOD FOR THE PRODUCTION OF A H.PYLORI POLYPEPTIDE, A COMPOSITION OF A VACCINE, A PREPARED COMPOSITION PURIFIED BY H.
AR020048A1 (en) A DEPENDENT POLYPEPTIDE OF VITAMIN K, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, ISOLATED NUCLEIC UNCODE THAT CODIFIES SUCH POLYPEPTIDE AND A HOSPED MAMIFEROUS CELL.
SE7705432L (en) POLYPEPTIME AND SET FOR ITS PREPARATION
ES2187527T3 (en) SUPERIOR ORDER STRUCTURE AND PEPTIDIC NUCLEIC ACIDS LINK.
NL300017I1 (en) Substituted androsta-1,4-diene-3,17-dione, as well as pharmaceutical preparations containing such compounds.
ES2124373T3 (en) PROCEDURE FOR THE PREPARATION OF ACID DERIVATIVES N-ACIL-N, N ', N'-ETILENDIAMINTRIACETICO.
ES2114539T3 (en) EXPRESSION OF RECOMBINED POLYPEPTIDES WITH IMPROVED PURIFICATION.
EP0165033A3 (en) Conformationally restricted thymopentin-like compounds
ATE171216T1 (en) EXPRESSION AND PURIFICATION OF RECOMBINANT SOLUBLE TISSUE FACTOR
ES2060594T3 (en) PROCESS TO PURIFY RECOMBINANT PROTEINS AND USE OF THEIR PRODUCTS.
AU6733487A (en) Mammalian interleukin-4
ES444558A1 (en) Production of long acting insulin preparations
DK289285A (en) THYMOPENTIN ANALOGUE
FI854227A0 (en) Process for the preparation of polypeptides useful as analgesic agent
KR840009069A (en) Method for producing psychotropic peptides
AR009600A1 (en) SEQUENCE OF NUCLEIC ACID AND AMINO ACIDS RELATED TO HELICOBACTER PYLORI AND VACCINE COMPOSITIONS OF THE SAME.
AR013618A1 (en) METHOD AND COMPOSITIONS FOR THE DISTRIBUTION AND EXPRESSION OF NUCLEIC ACIDS OF INTERFERON
AU4765396A (en) Method of preparing retroviral protease inhibitor intermediates
PT91776A (en) PROCESS FOR THE PREPARATION OF PEPTOLIDOS CONTAINING PIPECOLIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AU583388B2 (en) High performance liquid chromatography mobile phase
DK0707473T3 (en) Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymer beads
ES2083387T3 (en) SYNTHETIC PEPTIDES AND THEIR MIXTURES FOR THE DETECTION OF HIV ANTIBODIES.
AU525695B2 (en) Pharmaceutical formulations of prostacyclin
AR004377A1 (en) A BIOLOGICALLY ACTIVE PROTEIN INHIBITING KAPA B (NF k B), A NUCLEIC ACID SEQUENCE, A VECTOR OF EXPRESSION, AN ANTIBODY CONTRADICHA PROTEIN, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH PROTEIN FOR THE PREPARATION PHARMACEUTICALS.
KR890008166A (en) Selective degradation of fusion proteins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal